Ocular Therapeutix

Ocular is committed to redefining the retina experience across drug development, treatment, and outcomes. Our team has unmatched expertise and an impressive track record of innovation in retinal disease.

We have sharpened our focus on a single, bold mission – to redefine the retina experience – starting with wet age-related macular degeneration (AMD) as our top priority. There is a significant opportunity to also expand into non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME), where millions remain untreated.